Novo Nordisk raises full-year forecast
Photo: Richard Drew/AP/TT

Novo Nordisk raises full-year forecast on strong Wegovy demand

Danish pharmaceutical giant Novo Nordisk is raising its full-year forecasts - thanks to strong demand for the weight loss drug Wegovy.

Advertisement

The forecast for both adjusted sales growth and adjusted operating profit for the full year is expected to end at 0 to a decline of 6 percent at constant exchange rates, compared with a previously expected decline of 4-12 percent.

Adjusted sales in the second quarter of this year rose 7 percent to 78.5 billion Danish kroner compared with the same period last year, beating analysts' expectations of 71.6 billion Danish kroner.

Adjusted operating profit increased 11 percent year-on-year to DKK 33.4 billion, compared with an expected DKK 28.9 billion.

The company launched a new tablet form of Wegovy in the US in January - where it has been a huge success - and the tablet was recently approved for use in Europe.

In this story
AuthorTT News AgencyEnglish edition by Sweden Herald, adapted for our readers
Was this useful?

What do you think?

Keep readingmore from Business

All